Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINDway tafasitamab plus lenalidomide dose-optimization study in relapsed/refractory diffuse large B-cell lymphoma
MOH_2022-08-08_011962Phase 2Not yet recruiting
- Sponsor
- MorphoSys AG
- Start
- Jul 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tafasitamab and lenalidomide in diffuse large B-cell lymphoma (DLBCL) (3 cohorts), sponsored by MorphoSys AG. Primary endpoint: Primary endpoint not reported. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
tafasitamablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2022-08-08_011962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-08_011962.